MDVN 112.77 Medivation Inc $MDVN Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 9, 2014 at 3:37 AM

MDVN 112.77 Medivation Inc $MDVN Hit a 52 week high of 113.61 Currently at 112.77 +7.82 +7.45% With a day low of 102.04 and a total volume of 3,281,900.

MDVN Medivation Inc Recent Headline News

Look for Shares of Medivation to Potentially Pullback after Yesterday's 7.45% Rise
Comtex SmarTrend(R) - Fri Nov 07, 3:46PM CST
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $102.04 to a high of $113.61. Yesterday, the shares gained 7.5%, which took the trading range above the 3-day high of $106.79 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDVN: 112.77 (+7.82)

Clarification: Earns-Medivation story
AP - Fri Nov 07, 11:53AM CST
SAN FRANCISCO (AP) — In a story Nov. 7, The Associated Press reported that Medivation Inc. missed third-quarter earnings and revenue expectations based on the average of seven forecasts from Zacks Investment Research. The story was later updated to reflect that the company beat expectations based on the average of 18 estimates from FactSet.
MDVN: 112.77 (+7.82)

Medivation Q3 Earnings, Revenues Lag Estimates - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Nov 07, 11:08AM CST
Medivation's (MDVN) Xtandi should see strong uptake in the chemo-naive patient population from the fourth quarter.
CYTK: 4.10 (-0.15), MDVN: 112.77 (+7.82), BIIB: 320.75 (-2.72)

Medivation Hits High After Q3 Earnings Beat
at Investor's Business Daily - Fri Nov 07, 10:15AM CST
Biotech Medivation (MDVN) jumped to a new high in the stock market today after its Q3 results beat estimates late Thursday on strong sales of cancer drug Xtandi. Medivation's earnings totaled 96 cents a share, reversing a year-earlier loss and...
MDVN: 112.77 (+7.82), AOL: 42.68 (+0.45), AZN: 72.88 (+0.03)

Medivation Reports Third Quarter Financial Results and Provides Corporate Update
Marketwired - Thu Nov 06, 3:13PM CST
Medivation, Inc. (NASDAQ: MDVN) today reported its financial results for the third quarter ended September 30, 2014. U.S. net sales of XTANDI(R) (enzalutamide) capsules for the quarter, as reported by Astellas Pharma Inc., were $181.4 million (+67% vs. prior year). Ex-U.S. net sales of XTANDI for the quarter, as reported by Astellas, were $119.6 million.
MDVN: 112.77 (+7.82)

Medivation Announces Participation at Upcoming Investor Conference
Marketwired - Wed Nov 05, 3:11PM CST
Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conference:
MDVN: 112.77 (+7.82)

3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 112.77 (+7.82), ENDP: 68.96 (-1.23), AUXL: 32.75 (-0.52), SHPG: 198.58 (-1.37), DNDN: 0.94 (+0.11), SNSS: 1.63 (-0.05), ABBV: 61.50 (-1.21), SNY: 45.69 (-0.17), MNKD: 5.78 (+0.07), XOMA: 3.81 (-0.31)

Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline
at The Street - Wed Nov 05, 7:00AM CST
The diversification away from Xtandi has only just begun.
MDVN: 112.77 (+7.82)

Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:45PM CST
Perrigo (PRGO), which is scheduled to report first-quarter fiscal 2015 results on Nov 6, had delivered a positive earnings surprise of 12.26%.
MDVN: 112.77 (+7.82), ACT: 245.91 (-4.47), PRGO: 155.77 (+3.28), ALNY: 95.84 (+2.93)

Will Humana (HUM) Miss on Earnings Estimates this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 2:50PM CST
Humana Inc. (HUM) is set to report third-quarter 2014 earnings results on Nov 7, 2014.
MACK: 8.70 (-0.07), MDVN: 112.77 (+7.82), ALNY: 95.84 (+2.93), HUM: 130.58 (-9.29)

Geron Q3 Loss Wider, Shares Up on Removal of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Nov 04, 8:00AM CST
Geron's (GERN) third quarter results were totally overshadowed by the removal of the full clinical hold on the IND application for imetelstat.
CYTK: 4.10 (-0.15), MDVN: 112.77 (+7.82), BIIB: 320.75 (-2.72), GERN: 2.33 (-0.07)

Geron Corporation (GERN) Looks Strong: Stock Up 25.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:44AM CST
Geron Corporation (GERN) was a big mover last session, as the company saw its shares surge nearly 26% on the day
MDVN: 112.77 (+7.82), ONCY: 0.70 (+0.08), GERN: 2.33 (-0.07), ILMN: 186.35 (-3.52)

Is Hospira (HSP) Poised to Beat Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 4:00PM CST
Hospira (HSP), which is scheduled to report third-quarter 2014 results on Nov 6, had posted a positive earnings surprise of 28.57%.
MDVN: 112.77 (+7.82), ACT: 245.91 (-4.47), ALNY: 95.84 (+2.93), HSP: 56.32 (-0.32)

Will DaVita Healthcare (DVA) Disappoint Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 1:40PM CST
DaVita Healthcare Partners, Inc. (DVA) is set to report third-quarter 2014 earnings on Nov 6, 2014.
MDVN: 112.77 (+7.82), AMSG: 51.50 (+0.16), DVA: 74.49 (-3.54), ALNY: 95.84 (+2.93)

Seattle Genetics Gains on Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 11:50AM CST
Seattle Genetics, Inc. (SGEN) reported a loss of 13 cents per share in the third quarter, narrower than the Zacks Consensus Estimate of a loss of 25 cents.
MDVN: 112.77 (+7.82), BIIB: 320.75 (-2.72), SGEN: 36.05 (+1.20), GILD: 106.45 (-0.49)

Prosensa Holding N.V. (RNA) Jumps: Stock Moves Up 9.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:39AM CST
Prosensa Holding N.V. (RNA) was a big mover last session, as its shares rose nearly 10% on the day.
MDVN: 112.77 (+7.82), MACK: 8.70 (-0.07), RNA: 12.14 (+0.08), ILMN: 186.35 (-3.52)

Alder Biopharmaceuticals (ALDR) Jumps: Stock Rises 6.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 7:51AM CST
Alder Biopharmaceuticals Inc. (ALDR) was a big mover last session, as its shares rose nearly 7% on the day.
MDVN: 112.77 (+7.82), MACK: 8.70 (-0.07), ALDR: 16.57 (-0.25), ILMN: 186.35 (-3.52)

Oncolytics Biotech (ONCY) Looks Strong: Stock Up 21.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 7:44AM CST
Oncolytics Biotech Inc. (ONCY) was a big mover last session, as the company saw its shares surge nearly 22% on the day
MACK: 8.70 (-0.07), MDVN: 112.77 (+7.82), ONCY: 0.70 (+0.08), ILMN: 186.35 (-3.52)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tiger Group to Auction Huge Window Manufacturing Plant

Glass & Vinyl Ambitions: A New Chapter Who would have guessed? The seasoned window maker Showcase Window and Door Company is putting its prime manufacturing facility up for grabs. The online auction, orchestrated by Tiger Group, kicks off September 10, and it's sure to stir up some excitement in the industry. With picking up operations now within reach, it feels like...

AI Startup Shuttlebase Navigates Name Clash with Change

When Two AI Giants Collide Every so often, we get a clash of titans in the business world, and this time it's in the AI universe. New York's Moonshot AI, a champ in autonomous website optimization, hit a bump when its name collided with a Chinese counterpart, also called Moonshot AI. And just like that, the NY company had to chuck their name out the window and don a new...

Strategic Hire: Whisenhunt Joins FlexScreen & RiteScreen

Shaking Up the Window Screens Biz If you've been grinding in the window and door game, you know it's not an industry with a lot of buzz, but here comes a shot of caffeine. FlexScreen and RiteScreen just snagged David Whisenhunt to rev up their sales machine. Who's David Whisenhunt? Well, he's no rookie. With over two decades deep in the fenestration field, Whisenhunt...

Alif Semiconductor Unveils StartKit for Edge AI MCU Fam

Here's some clarity amidst the storm of buzzwords: Alif Semiconductor has rolled out something the market's been howling for—Edge AI that doesn't break the bank. It's less about slick press releases and more about real-world implications. We're talking accessibility with their dirt-cheap, small-form-factor StartKit platform for Ensemble and Balletto microcontrollers....

Jollibee and DreamWorks Unite for Cultural Celebration

Jollibee Partners with DreamWorks Animation Never thought I’d see the day: Jollibee, that familiar face of fast food, teaming up with the creative juggernaut DreamWorks Animation. They’re calling it a celebration of friendship and Filipino culture, wrapped up neatly in the context of a flick called Forgotten Island. Set to sizzle in theaters on September 25, 2026,...

Innventure Faces Major Lawsuit Amidst Market Turmoil

The Plot Thickens with Innventure's DarkNX Project Buckle up, fellow market sling-riders; the Innventure tale is a rocky one for the books. Imagine this: You’ve plunked down your hard-earned cash on Innventure Inc. (NASDAQ: INV), lured by their glowing pronouncements about a supposed golden egg project, the Accelsius DarkNX data-center deal. A big talk about...

Celebree Elevates Early Ed with New Certification Push

A New Standard in Early Childhood Education In the cutthroat world of childcare and early education, just meeting the state standards ain't cutting it anymore. Celebree School, known for its infant, toddler, and preschool programs, is shaking things up with its 'Celebree Certified' initiative, setting a brand-new benchmark for teacher readiness that's far beyond the usual...

Illinois' Legal Tangle: Feds Under Fire?

What a tangled web Illinois lawmakers have woven this time. They've gone and cooked up a pair of laws with a real knack for attracting attention—specifically from the folks over at the National Police Association (NPA). These aren’t your run-of-the-mill rules; they feel more like a blueprint for putting federal officers through the legal wringer and turning courtroom...

The Austin Company to Showcase at ISPE Annual Event

Setting the Stage at ISPE Expo When you think of pharmaceuticals and the bustle behind closed doors, it's with companies like The Austin Company leading the charge. This October, they're strutting their stuff at the ISPE Annual Meeting and Expo. No small potatoes here—it's at the Gaylord National in Maryland. Mark those dates: October 18-21, 2026. It's a circus of...

Big Wins at Americas Cardroom's $15M Venom Series

High Stakes and Huge Paydays: The Venom Breakdown Alright, folks, here's a tale of how the cards fell in one of the most electrifying poker standoffs at Americas Cardroom. With prize pools clocking in at a staggering $15.095 million, the Dual Mystery Bounty Venoms really stacked the chips high. From the gritty, bustling halls of the internet to the proverbial green-felt...